A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial


Akman Demir G., Turkoglu R., Saip S., Yuceyar N., EFENDİ H., TURAN Ö. F., ...More

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.4, pp.253-257, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 56 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.5152/npa.2017.20515
  • Journal Name: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.253-257
  • Keywords: Multiple sclerosis, fingolimod, patient satisfaction, quality of life, ORAL FINGOLIMOD, INTRAMUSCULAR INTERFERON, DOUBLE-BLIND, SAFETY, THERAPIES, EFFICACY, OUTCOMES, ACETATE, PHASE-3, SWITCH
  • Karadeniz Technical University Affiliated: Yes

Abstract

Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.